FDA advisory panel votes 16-0 to recommend semaglutide for type 2 diabetes

On October 18, 2017, an FDA advisory committee voted 16-0 in favor of approving once-weekly semaglutide for type 2 diabetes ^[1]. The vote was a recommendation to the agency, and the FDA's own approval decision followed about seven weeks later ^[1].

Semaglutide is a glucagon-like peptide-1 (GLP-1) analog, a synthetic version of a naturally occurring hormone ^[1]. It selectively binds to and activates the GLP-1 receptor, which stimulates insulin secretion and lowers glucagon secretion when blood glucose is high ^[1]. Novo Nordisk filed its application for the once-weekly form with the FDA on December 5, 2016, and the committee vote came roughly ten months into that review ^[1].

The approval that followed

The FDA approved the drug on December 5, 2017, under the brand name Ozempic, as an injection for adults with type 2 diabetes ^[1]. The label describes it as an adjunct to diet and exercise to improve blood sugar control ^[1]. It is given as an injection under the skin once a week, at any time of day, with or without meals ^[1]. The committee's discussion that day and any conditions it placed on its vote have not been reported ^[1].

Semaglutide has since been approved under several brand names and in different forms, each with its own approved uses ^[1]:

• Rybelsus, a daily tablet, was first approved September 20, 2019, for type 2 diabetes ^[1].
• Wegovy, a higher-dose weekly injection, was first approved June 4, 2021, for weight reduction in adults with obesity or overweight ^[1].
• Ozempic's approved uses expanded on January 16, 2020, to include reducing the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease ^[1].
• A higher-dose 2 mg version of Ozempic was approved March 28, 2022 ^[1].
• On January 28, 2025, Ozempic became approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease ^[1].
• A reformulated oral semaglutide was approved December 9, 2024, and rebranded as Ozempic tablets on January 30, 2026 ^[1]. Wegovy tablets were approved December 22, 2025 ^[1].

Safety information on the label

Ozempic carries a boxed warning for thyroid C-cell tumors ^[1]. Warnings and precautions listed on the label include acute pancreatitis, diabetic retinopathy complications, low blood sugar, acute kidney injury due to volume depletion, severe gastrointestinal reactions, serious hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation ^[1]. The most common side effects, reported in at least 5 percent of patients, include nausea, vomiting, diarrhea, abdominal pain and constipation ^[1].

Why it matters for patients

An advisory committee vote is not an approval. The 16-0 result was one input in the FDA's review, and the drug only became available to patients after the agency issued its own decision on December 5, 2017 ^[1]. That distinction still matters when news reports describe committee votes on drugs that are not yet on the market.

The vote also opened the path for a molecule that is now sold under three brand names in the United States, with different approved uses. Ozempic, Rybelsus and Wegovy all contain semaglutide, but Ozempic and Rybelsus are approved for type 2 diabetes, while Wegovy is approved for weight reduction in people with obesity or overweight ^[1]. Their labels also differ in dose and in the conditions they are cleared to treat ^[1]. Patients comparing a prescription, a pharmacy receipt or an insurance letter may see any of these names.

What happens next

The step that followed the vote was the FDA's decision, which came on December 5, 2017 ^[1]. After that, the approvals listed above arrived in stages: oral semaglutide in 2019, Wegovy in 2021, the higher-dose Ozempic pen in 2022, the chronic kidney disease indication in January 2025, and tablet forms of Wegovy in December 2025 ^[1]. The page tracking these approvals was last updated April 23, 2026 ^[1].